---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors"
date: 2026-02-04 21:45:56 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-19199
original_published: 2025-10-02 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors

**Published:** February 04, 2026 21:45 UTC
**Source:** Federal Register
**Original Published:** October 02, 2025 00:00 UTC
**Document Number:** 2025-19199

## Summary

The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Stage One Immunotherapeutics, Inc., incorporated in Delaware and with headquarters in Pennsylvania.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/10/02/2025-19199/prospective-grant-of-an-exclusive-patent-license-substituted-quinoline-analogs-as-aldehyde)
- API: https://www.federalregister.gov/api/v1/documents/2025-19199

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
